admin – Page 3337 – Get News Story

Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034, Driven by Recent FDA Approvals and Positive Clinical Trial Outcomes | DelveInsight

“Myasthenia Gravis – Market Insight, Epidemiology And Market Forecast – 2034”

The Myasthenia Gravis treatment market is projected to experience significant expansion in the coming years, propelled by the development of innovative therapies from key myasthenia gravis companies including Horizon Therapeutics, Amgen, Janssen Research & Development, Hoffmann-La Roche, Immunovant Sciences GmbH, Alexion, AstraZeneca Rare Disease, Regeneron Pharmaceuticals, Kyverna Therapeutics, and Cartesian Therapeutics, among others.

DelveInsight’s “Myasthenia Gravis – Market Insight, Epidemiology And Market Forecast – 2034” report provides comprehensive insights into the historical and forecasted myasthenia gravis epidemiology, as well as market trends across the 7MM (United States, EU4 countries including Germany, France, Italy, and Spain, along with the United Kingdom, and Japan). The myasthenia gravis market size in the 7MM reached approximately USD 5 billion in 2023, with projections indicating substantial growth throughout the forecast period (2024-2034). This expansion is primarily driven by increasing disease prevalence, enhanced diagnostic capabilities, and the anticipated launch of novel therapeutic options targeting specific disease mechanisms.

According to DelveInsight’s analysis, the US dominated the myasthenia gravis market in 2023, representing nearly 76% of the total market share. This dominance is attributed to favorable reimbursement policies, high healthcare expenditure, and rapid adoption of innovative therapies. The EU4 countries and the United Kingdom collectively form the second-largest market, followed by Japan, which is expected to experience significant growth during the forecast period.

Download the Myasthenia Gravis Market Forecast Report to understand which factors are driving the Myasthenia Gravis market @ Myasthenia Gravis Market Trends.

The report also delivers detailed epidemiological insights, indicating that total diagnosed myasthenia gravis prevalent cases across 7MM were approximately 300K in 2023, with the US accounting for approximately 130K cases. EU4 and the UK together accounted for nearly 125K diagnosed prevalent cases, while Japan reported a little more than 32K cases. These figures are projected to increase at a notable CAGR throughout the study period (2020-2034).

Discover evolving trends in the Myasthenia Gravis patient pool forecasts @ Myasthenia Gravis Epidemiological Analysis.

The current myasthenia gravis treatment landscape encompasses cholinesterase enzyme inhibitors, immunosuppressive medications, and biological therapies. VYVGART (efgartigimod alfa-fcab), developed by Argenx, has established itself as a groundbreaking FcRn blocker approved in multiple regions for treating generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody-positive. Other significant therapies in the market include SOLIRIS and ULTOMIRIS, manufactured by Alexion Pharmaceuticals, which have demonstrated efficacy in managing refractory cases.

The myasthenia gravis pipeline is robust, with several promising therapies in late-stage clinical development. Batoclimab from Immunovant Sciences GmbH has shown positive results in Phase III studies, demonstrating significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores. Additionally, DESCARTES-08, Cartesian Therapeutics’ RNA CAR T-cell therapy specifically designed for autoimmune diseases, represents an innovative approach in the treatment paradigm.

In a notable recent development, Cartesian Therapeutics announced in January 2025 that it received a written agreement from the FDA under the Special Protocol Assessment (SPA) process for the design of its planned Phase III AURORA trial for Descartes-08, its lead mRNA cell therapy candidate targeting myasthenia gravis. This milestone underscores the evolving treatment landscape and highlights the industry’s commitment to addressing the unmet medical needs of the myasthenia gravis patient population.

Additionally, in April 2025, the FDA approved Johnson & Johnson’s nipocalimab, marketed as IMAAVY, as a new treatment for adults and pediatric patients aged 12 years and older who have generalized myasthenia gravis and are anti-acetylcholine receptor or anti-muscle-specific kinase antibody positive.

Promising myasthenia gravis therapeutic updates also include positive outcomes and steroid-sparing effects from inebilizumab. Furthermore, new safety and efficacy data have emerged for efgartigimod, rozanolixizumab, nipocalimab, and complement inhibitors such as zilucoplan and ravulizumab.

Discover evolving trends in the Myasthenia Gravis treatment landscape @ Myasthenia Gravis Recent Developments.

DelveInsight’s analysis indicates that the myasthenia gravis market is highly competitive and rapidly evolving, with leading pharmaceutical companies such as Roche (SWX: ROG), UCB Pharma (EBR: UCB), Alexion Pharmaceuticals (NASDAQ: ALXN), Mitsubishi Tanabe Pharma (MTZPY), Sanofi (EPA: SAN), Grifols (BME: GRF), Amgen (NASDAQ: AMGN), Eisai (TYO: 4523), Merck & Co. (NYSE: MRK), Novartis (SWX: NOVN), GlaxoSmithKline (LON: GSK), AbbVie (NYSE: ABBV), Teva Pharmaceutical (TLV: TEVA), Sandoz (SWX: SDZ), Argenx (EBR: ARGX), Bristol-Myers Squibb (NYSE: BMY), and Catalysts Pharmaceuticals (NASDAQ: CPRX), among others, are actively developing and marketing treatments.

The integration of innovative treatment modalities, including FcRn inhibitors and cell therapies, is expected to significantly improve patient outcomes in this rare autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. However, challenges such as high treatment costs and limited accessibility in certain regions continue to impact market dynamics.

As research advances and clinical trials progress, the myasthenia gravis market is expected to witness a paradigm shift in treatment approaches, moving toward more personalized therapeutic strategies based on antibody serological profiles and disease severity classifications. This evolution, coupled with increasing disease awareness and improved diagnostic capabilities, will continue to drive market growth and address the myasthenia gravis patients unmet needs.

Table of Contents

1. Key Insights

2. Report Introduction

3. Myasthenia Gravis Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Myasthenia Gravis Epidemiology and Patient Population

9. Myasthenia Gravis Patient Journey

10. Myasthenia Gravis Marketed Therapies

11. Myasthenia Gravis Emerging Therapies

12. Myasthenia Gravis: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Myasthenia Gravis Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Myasthenia Gravis Pipeline Insight

Myasthenia Gravis Pipeline Insight provides comprehensive insights about the Myasthenia Gravis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Myasthenia Gravis companies, including Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., and Alexion Pharmaceuticals Inc, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034, Driven by Recent FDA Approvals and Positive Clinical Trial Outcomes | DelveInsight

Migraine Market Size Projected to Grow Rapidly by 2034, Driven by Recent FDA Approvals and Emerging Therapies | DelveInsight

“Migraine Market Insight, Epidemiology And Market Forecast – 2034”

The migraine therapeutics market is experiencing robust growth. Key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma, Ionis Pharmaceuticals, and Charleston Laboratories, among others, are actively developing next-generation therapies targeting novel mechanisms of action to address the unmet needs.

DelveInsight’s “Migraine Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the current migraine treatment market, emerging therapeutics, and market trends shaping the future of migraine management across the US, EU4 (Germany, Spain, Italy, and France), the UK, and Japan. According to DelveInsight’s migraine report, the total migraine market size in the 7MM was approximately USD 11 billion in 2023 and is projected to increase with a decent CAGR during the forecast period (2024-2034).

Furthermore, the US dominated the migraine market in 2023, accounting for approximately USD 7 billion, which is expected to increase by 2034 as innovative therapeutic approaches gain traction.

Download the Migraine Market Forecast Report to understand which factors are driving the Migraine market @ Migraine Market Trends.

The migraine patient population continues to expand, with approximately 120K prevalent cases reported across the 7MM in 2023. The US represents the largest patient share at nearly 40%, followed by Japan at 15%. The UK leads among European nations. Furthermore, gender disparities remain pronounced, with females constituting approximately three times the number of cases compared to males in the US. Epidemiological patterns further reveal that episodic migraine significantly outweighs chronic migraine in prevalence. From a commercial perspective, both forms contribute substantially to the overall disease burden and market opportunity.

Discover evolving trends in the Migraine patient pool forecasts @ Migraine Epidemiological Analysis.

Current therapeutic approaches primarily focus on acute/abortive and preventive strategies. The acute migraine treatment market is dominated by triptans, which generate the highest revenue, followed by NSAIDs, analgesics/opioids, and dihydroergotamine formulations. For preventive therapy, options include antiepileptics, antihypertensives, and neurotoxins like BOTOX, which remains the only FDA-approved therapy specifically for chronic migraine treatment. The identification of key biomarkers, particularly serotonin 1F receptor and calcitonin gene-related peptide (CGRP), has revolutionised treatment approaches, with CGRP antagonists like Eli Lilly’s EMGALITY (galcanezumab-gnlm) and Teva’s AJOVY (fremanezumab-vfrm) securing significant market share.

Recent regulatory milestones have accelerated market growth by introducing several significant approvals that expand treatment options for the diverse patient population. In January 2025, the FDA approved Axsome Therapeutics’ AXS-07, marketed as SYMBRAVO, a novel oral medication that is rapidly absorbed and employs multiple mechanisms to treat acute migraines in adults, with or without aura. Additionally, in February 2025, the FDA cleared a migraine device designed for children as young as eight years old. In November 2024, Theranica’s Nerivio REN wearable received expanded age indications, making it the first FDA-cleared non-drug therapy for acute migraine treatment in children, as well as the only prescribed preventive migraine treatment for this age group.

In April 2025, the FDA approved CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in adults, to be used alongside existing migraine therapies. Delivered via a 12-week smartphone app, CT-132 significantly reduced monthly migraine days and improved quality of life in clinical trials, offering a novel, accessible non-drug option for migraine prevention.

Discover evolving trends in the Migraine treatment landscape @ Migraine Recent Developments.

The competitive landscape features several key pharmaceutical players driving innovation in the migraine therapeutics market, including Lundbeck Seattle BioPharmaceutical, Eli Lilly (NYSE: LLY) and Company, Amgen (NASDAQ: AMGN), Novartis (NYSE: NVS), Teva Pharmaceuticals (NYSE: TEVA), Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs (NYSE: RDY), AbbVie (NYSE: ABBV), Impel NeuroPharma (NASDAQ: IMPL), Zosano Pharma (NASDAQ: ZSAN), Axsome Therapeutics (NASDAQ: AXSM), Aeon Biopharma (NYSE: AEON), Ionis Pharmaceuticals (NASDAQ: IONS), and Charleston Laboratories, among others. These companies are actively developing next-generation therapies targeting novel mechanisms of action to address treatment gaps in both episodic and chronic migraine management.

Looking ahead, the migraine drugs market is poised for further transformation through emerging pipeline candidates with novel mechanisms of action and improved efficacy profiles. The continued focus on personalised treatment approaches, enhanced diagnostic tools, and expanding patient awareness is expected to drive sustained market growth, offering new hope for millions of individuals worldwide affected by this debilitating neurological condition.

Table of Contents

1. Key Insights

2. Report Introduction

3. Migraine Market Overview at a Glance

4. Executive Summary of Migraine

5. Disease Background and Overview

6. Migraine Treatment

7. Migraine Epidemiology and Patient Population

8. Migraine Patient Journey

9. Migraine Patient Journey

10. Migraine Marketed Therapies

11. Migraine Emerging Therapies

12. Migraine: 7 Major Market Analysis

13. Migraine Market Outlook

14. KOL Views

15. Migraine Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

Migraine Pipeline Insight

Migraine Pipeline Insight provides comprehensive insights about the Migraine pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Migraine companies, including Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, and Pear Therapeutics, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Market Size Projected to Grow Rapidly by 2034, Driven by Recent FDA Approvals and Emerging Therapies | DelveInsight

Cybersecurity is Protecting Personal Information and Worth adding to Portfolios

Now IS the right time to move into Cybersecurity stocks amid a flurry of high profile hacking incidents. The buzz surrounding AI is driving investor interest in Cybersecurity stocks. The economic impact of President Donald Trump’s tariff-based trade policies are a wild card regarding the Stock Market.

Cybersecurity’s growing role in cloud computing became clear when Google-parent Alphabet ($GOOG) agreed to buy fast growing cybersecurity firm Wiz in an all-cash $32 Billion Dollar deal. Also, Wiz recently entered a strategic partnership with Check Point Software Technologies ($CHKP).

Wall Street analysts expect corporate spending on Cybersecurity to remain a priority over most other software products and services.

“Cybersecurity stocks such as Palo Alto ($PANW), Zscaler ($ZS), CrowdStrike ($CRWD), Checkpoint ($CHKP), CyberArk ($CYBR), Fortinet ($FTNT), Okta ($OKTA) and Cloudflare ($NET) will be defensive names where investors could rotate from Semi-Conductors to software to hunker down during this Category F5 ($FFIV) storm and likely outperform other subsets of tech,” said Wedbush analyst Daniel Ives in a report.

Like rival CrowdStrike, Palo Alto Networks is adding more artificial intelligence to computer security products. Cybersecurity firms, like software companies generally, are now turning to autonomous, goal-drive AI Agents.

One stock that is Affordable and Undervalued at .46 cents is posting some Impressive Numbers, Cycurion, Inc. NASDAQ: ($CYCU). Why is this stock Trading at .46 with these Sound numbers and the turnaround shown here:

• 2024 Total Revenue of 17.8 Million with Adjusted EBITDA of $2.3 Million, +58.9% y/y with Expanded Margin of 12.9% vs $1.4 Million in FY2023.

• Net Income of $1.2 Million Marking First Full Year of Net Profitability.

• Earnings Per Share Improvement to $0.07 Basic and $0.01 Fully Diluted, Versus $(0.14) in Both Categories for FY2023.

• Cybersecurity Leader Addressing the Growing Threat of Cyber Attacks and Data Breaches with a Multi-layered SaaS Solution.

• Serving Some of the Most Complex Government Agencies and Corporations in the World Including Fortune 100 and 500 Companies.

• Clients and Partners Include: US Dept. of Defense, Defense Intelligence Agency, Dept. of Homeland Security, US Navy and Major Private Sector Companies.

• Delivering State-of the-Art, Al-Infused Proprietary Technology Being One of the First to Marry AI and Cybersecurity.

• $6 Million Contract Award by Major Municipal Transportation Agency.

• Expansion into Latin America via Partnership with LSV-TECH International Extending Sales Presence Into 135 Countries via Nokia ($NOK) Agreement.

• With High Product Pargins, the ARx Security Platform is a Cybersecurity Breakthrough and the Foundational Future Contributor to CYCU growth.

• Technology Veterans, Many Holding High-Level Security Clearances and Have Served Critical Roles in Public and Private Sectors.

Here could be why: The Entire Stock Float is ONLY 25 Million Shares, yet it is depressed Every Single Day…

^^^^ 1 Million shares LISTED as Short and we suspect it is MUCH Greater ^^^^

Merely take a look at Cycurion Inc. (NASDAQ: CYCU). Put it on your Watchlist. This NASDAQ Cybersecurity Stock could be a sleeping Giant.

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Cycurion, Inc.
Contact Person: Kevin Kelly, Chairman & CEO
Email: Send Email
Phone: 888-341-6680
Address:1640 Boro Place 4th Floor
City: McLean
State: Virginia
Country: United States
Website: www.cycurion.com

Hormone Replacement Therapy Market Set to Grow at a Robust CAGR of 6.5% Through 2030, Fueled by Rising Menopausal Population and Novel Treatment Approaches | DelveInsight

“Hormone Replacement Therapy Market Report”

Key hormone replacement therapy companies include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Ascendis Pharma, Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc and several others.

DelveInsight’s “Hormone Replacement Therapy – Market Insights, Competitive Landscape, and Market Forecast – 2030” report provides an in-depth understanding of the hormone replacement therapy market trends, key drivers, emerging technologies, and competitive landscape across global regions. The global hormone replacement therapy market is poised for substantial expansion, with projections indicating a steady CAGR of 6.5% from 2024 to 2030. This growth trajectory reflects the increasing prevalence of hormonal disorders worldwide, coupled with an aging population and significant advancements in therapeutic options addressing various endocrine conditions across all major markets.

North America currently dominates the hormone replacement therapy treatment landscape and is expected to maintain this leadership position throughout the forecast period. This regional prominence is attributed to several factors, including the high prevalence of hormonal disorders, advanced healthcare infrastructure, and favorable reimbursement policies.

Download the Hormone Replacement Therapy Market Forecast Report to understand which factors are driving the hormone replacement therapy market @ Hormone Replacement Therapy Market Trends.

The report segments the hormone replacement therapy market by therapy type, indication, route of administration, and geography. The hormone replacement therapy market by therapy type encompasses Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and other specialized hormone therapies. Among these segments, treatments targeting menopausal symptoms currently dominate the market, driven by the substantial demographic of women experiencing menopause globally. Furthermore, the male hypogonadism therapy market is also experiencing significant growth, with prevalence rates reported between 10 and 55% in patients with specific underlying conditions.

According to the hormone replacement therapy epidemiological data, the worldwide average age for menopause onset hovers around 50 years, with women at this age experiencing significant decreases in estrogen and progesterone production, triggering various symptoms that necessitate hormonal intervention. The World Health Organization reported that in 2021, women aged 50 and over constituted approximately 26% of the female global population, representing a substantial patient pool requiring management of menopausal symptoms such as vasomotor symptoms (VMS), commonly known as hot flashes and night sweats.

Discover evolving trends in the hormone replacement therapy patient pool forecasts @ Hormone Replacement Therapy Epidemiological Analysis.

The competitive landscape includes big pharmaceutical companies and specialized players actively developing innovative hormone replacement therapy solutions. Key market participants include Abbott (NYSE: ABT), Novartis AG (SIX Swiss Exchange: NOVN), Pfizer Inc. (NYSE: PFE), Merck KGaA (NYSE: MRK), Bayer AG (NYSE: BAYN), Halozyme Therapeutics (NASDAQ: HALO), Eli Lilly and Company (NYSE: LLY), Viatris Inc. (NASDAQ: VTRS), F. Hoffman-La Roche (OTC: RHHBY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN), AbbVie Inc. (NYSE: ABBV), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), Ascendis Pharma (NASDAQ: ASND), Vista Pharma, Inc. (BSE: 524711), Clarus Therapeutics, Inc. (NASDAQ: CRXT), Gedeon Richter Plc (Budapest Stock Exchange: RICHTER), Endo International plc (OTCQX: NDOI) and several others.

These companies are engaged in extensive research and development activities, strategic collaborations, and drug development for hormone replacement therapy, strengthening their market positions and addressing unmet medical needs.

Recent therapeutic advancements have substantially transformed the hormone replacement therapy landscape. A milestone development came in May 2023 when Astellas Pharma received FDA approval for VEOZAH, a treatment for moderate to severe VMS associated with menopause. This approval represents a significant innovation as a selective neurokinin 3 (NK3) receptor antagonist that addresses menopausal symptoms through a unique mechanism of action.

In June 2022, Halozyme Therapeutics announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment for testosterone replacement therapy in adult males with conditions associated with endogenous testosterone deficiency. Other notable developments include Pfizer’s relaunch of DUAVEE in June 2023 following a voluntary recall, now featuring improved packaging.

Additionally, in February 2025, the FDA announced significant labeling changes for all testosterone products, removing the boxed warning about increased risk of serious cardiovascular events-such as heart attack and stroke-that had been required since 2014, after the TRAVERSE trial demonstrated no increased incidence of major adverse cardiovascular events among men with hypogonadism and preexisting or high cardiovascular risk who received testosterone therapy compared to placebo.

Discover evolving trends in the hormone replacement therapy treatment landscape @ Hormone Replacement Therapy Recent Developments.

Despite robust growth projections, the HRT market faces challenges, including concerns regarding potential side effects of long-term hormone therapy use, particularly regarding liver function with some newer treatments like VEOZAH, which carries a Boxed Warning for risks of hepatotoxicity. Additionally, the complex regulatory approval process for new hormone therapies and varying reimbursement scenarios across different regions present obstacles to market expansion.

Looking ahead, the hormone replacement therapy market is expected to benefit from the introduction of innovative hormone delivery systems, personalized treatment approaches based on genetic profiling, and increased awareness about hormonal health management across all age groups. The development of bioidentical hormones and hormone therapies with improved safety profiles will likely reshape treatment paradigms and further drive market growth through 2030, creating significant opportunities for stakeholders across the hormone disorder treatment market.

Table of Contents

1. Hormone Replacement Therapy Market Report Introduction

2. Hormone Replacement Therapy Market Executive Summary

3. Hormone Replacement Therapy Competitive Landscape

4. Regulatory Analysis

5. Hormone Replacement Therapy Market Key Factors Analysis

6. Hormone Replacement Therapy Market Porter’s Five Forces Analysis

7. Hormone Replacement Therapy Market Assessment

8. Hormone Replacement Therapy Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hormone Replacement Therapy Market Set to Grow at a Robust CAGR of 6.5% Through 2030, Fueled by Rising Menopausal Population and Novel Treatment Approaches | DelveInsight

Calciphylaxis Market Poised for Notable Growth Through 2032, Driven by Rising Disease Awareness and Emerging Targeted Therapies | DelveInsight

“Calciphylaxis Market Report”

The calciphylaxis treatment market is poised for notable growth, fueled by increasing disease recognition, growing prevalence among end-stage renal disease patients, and the advancement of innovative therapies by key players, including Amgen, AbbVie, Pfizer, Sanofi, Keryx Biopharmaceuticals, Ardelyx, Mallinckrodt Pharmaceuticals, Hope Pharmaceuticals, Sanifit, and Vifor Pharma, among others.

DelveInsight’s “Calciphylaxis – Market Insight, Epidemiology And Market Forecast – 2032” report provides a comprehensive analysis of historical and forecasted calciphylaxis epidemiological trends across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report delivers valuable insights into calciphylaxis pathophysiology, current treatment practices, emerging therapies, and market dynamics that will shape the landscape over the next decade. This rare but devastating condition, characterized by painful skin lesions resulting from cutaneous arteriolar calcification, represents a significant unmet medical need with limited treatment options currently available.

According to DelveInsight analysis, the calciphylaxis treatment market is experiencing steady growth across 7MM, driven by a rising incidence of end-stage renal disease and associated risk factors like diabetes and obesity. Furthermore, the US is the largest market due to a high patient pool and ongoing innovation, while Europe and Japan are showing growth supported by advanced diagnostics and healthcare infrastructure.

Download the Calciphylaxis Market Forecast Report to understand which factors are driving the calciphylaxis market @ Calciphylaxis Market Trends.

According to epidemiological findings highlighted in the report, calciphylaxis demonstrates a notable gender disparity, with significantly higher incidence rates among female patients. This gender-specific pattern provides important demographic insights for healthcare planning and therapeutic development strategies.

The report segments the calciphylaxis patient population across important categories, including total incident cases of calciphylaxis in patients on hemodialysis, overall incident cases, and gender-specific incident distribution. This granular analysis provides stakeholders with crucial insights for strategic planning and resource allocation in addressing this challenging rare disease.

Discover evolving trends in the calciphylaxis patient pool forecasts @ Calciphylaxis Epidemiological Analysis.

The current calciphylaxis treatment approach necessitates a multidisciplinary intervention focusing on optimal wound management, appropriate antibiotic therapy for secondary infections, correction of biochemical abnormalities, avoidance of cutaneous trauma, and administration of sodium thiosulfate. However, the disease continues to carry high mortality rates primarily due to sepsis complications, underscoring the urgent need for more effective therapeutic options that can specifically target the underlying calciphylaxis pathophysiological mechanisms.

The calciphylaxis clinical trial pipeline is showing growing activity, with several promising therapies in development. Key drugs currently in the pipeline include SNF472, INZ-701, and intravenous sodium thiosulfate, among others. SNF472, developed by Sanifit, is a selective inhibitor of vascular calcification and is currently in Phase III clinical trials (CALCIPHYX). INZ-701, an enzyme replacement therapy designed to increase plasma pyrophosphate levels, has demonstrated positive interim results in Phase I and is expected to enter registrational trials soon. Sodium thiosulfate, already widely used off-label, has been evaluated in the CALISTA Phase III trial to better understand its efficacy and safety for calciphylaxis in hemodialysis patients.

DelveInsight’s analysis indicates that the calciphylaxis market is expected to witness significant expansion across the 7MM, driven by several key factors. These include the high prevalence of calciphylaxis in patients with end-stage renal disease, increasing disease awareness among healthcare providers, growing recognition of early symptoms, and the rising demand for effective treatment modalities. Additionally, advancements in diagnostic technologies driven by leading players such as Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), Sanofi (NASDAQ: SNY), Keryx Biopharmaceuticals, Ardelyx (NASDAQ: ARDX), Mallinckrodt Pharmaceuticals (MNKTQ), and Vifor Pharma, among others, are enabling earlier and more accurate identification of calciphylaxis, contributing to market growth by expanding the treatable patient population.

Discover evolving trends in the calciphylaxis treatment landscape @ Calciphylaxis Recent Developments.

Looking ahead, the calciphylaxis market landscape is expected to evolve significantly with the potential approval of novel therapeutic options, increased disease awareness, and improved diagnostic approaches. The introduction of targeted treatments like SNF472 could substantially reduce mortality rates and improve quality of life for patients suffering from this debilitating condition. However, challenges remain, including the need for enhanced understanding of disease pathogenesis, the development of standardized treatment protocols, and addressing the economic burden associated with managing this complex condition.

Table of Contents

1. Key Insights

2. Report Introduction

3. Calciphylaxis: Market Overview at a Glance

4. Executive Summary of Calciphylaxis

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Calciphylaxis: Disease Background and Overview

8. Calciphylaxis Treatment

9. Calciphylaxis Epidemiology and Patient Population

10. Calciphylaxis Emerging Drugs

11. Calciphylaxis: Seven Major Market Analysis

12. KOL Views

13. SWOT Analysis

14. Calciphylaxis Unmet Needs

15. Reimbursement and Market Access of Calciphylaxis

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Related Reports

Calciphylaxis Pipeline Insight

Calciphylaxis Pipeline Insight provides comprehensive insights about the calciphylaxis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the calciphylaxis companies, including Hope Pharmaceuticals, Sanifit, Alexion Pharmaceuticals, Epizon Pharma, and Rectify Pharma, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Calciphylaxis Market Poised for Notable Growth Through 2032, Driven by Rising Disease Awareness and Emerging Targeted Therapies | DelveInsight

Congestive Heart Failure Market Poised for Substantial Growth by 2034, Driven by Emerging Cell Therapies and Recent FDA Approvals | DelveInsight

“Congestive Heart Failure Market Report”

The congestive heart failure therapeutics market is projected to witness substantial growth driven by rising prevalence, technological advancements, and innovative treatment options. Key pharmaceutical companies, including Novartis, Alnylam, Otsuka, AstraZeneca, Bayer, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Lexicon, Mesoblast, BioCardia, Cytokinetics, and others, are actively developing novel therapies to address significant unmet needs in this rapidly evolving landscape.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast- 2034” report delivers comprehensive insights into congestive heart failure, historical and forecasted epidemiology, and market trends across the seven major heart failure major markets, which include the US, EU4 countries (Germany, France, Italy, and Spain), the UK, and Japan. According to the analysis, the total chronic heart failure market size in the 7MM was approximately USD 7 billion in 2023 and is projected to grow significantly during the forecast period (2024-2034).

The US accounts for the largest market share of the total congestive heart failure market size and will continue to experience substantial growth throughout the forecast period. Among the EU4 and the UK, Germany contributes the highest revenue share, while the UK has the smallest market share. This regional disparity is attributed to varying prevalence rates, healthcare infrastructure differences, and reimbursement policies across markets.

Download the Congestive Heart Failure Market Forecast Report to understand which factors are driving the congestive heart failure market @ Congestive Heart Failure Market Trends.

From the epidemiological perspective, the total congestive heart failure patient pool in the 7MM was approximately 21 million in 2023, with males representing a higher share compared to females. Furthermore, the majority of heart failure cases occur in individuals aged 60 years and above. In 2023, this age group accounted for approximately 7 million heart failure cases in the US.

DelveInsight’s analysis segments this patient population by various parameters, including total diagnosed prevalent cases, gender-specific cases, age-specific cases, NYHA class-specific cases, ejection fraction-specific cases, and type-specific cases (acute and chronic). Heart failure with preserved ejection fraction (HFpEF) contributes to the majority of cases, while NYHA class II and class III represent the highest proportion among class-specific diagnosed prevalence.

The DelveInsight report also analyses the congestive heart failure drugs market and treatment landscape. The current congestive heart failure treatment landscape relies heavily on established drug classes like ACE inhibitors, ARBs, beta-blockers, and diuretics. Among the approved therapies, ENTRESTO (sacubitril/valsartan) from Novartis (SWX: NOVN) leads the market and is expected to maintain its dominant position during the forecast period, followed by beta blockers. However, with Novartis expecting to lose exclusivity in the United States in 2025, the introduction of generics poses a significant threat to this billion-dollar medication.

SGLT2 inhibitors such as JARDIANCE (empagliflozin) from Boehringer Ingelheim and Eli Lilly (NYSE: LLY), and FARXIGA (dapagliflozin) from AstraZeneca (LON: AZN) have gained substantial traction in the congestive heart failure therapeutic landscape. In June 2021, the European Commission granted marketing authorization for JARDIANCE as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction, followed by FDA approval in August 2021.

In March 2025, the FDA approved AMVUTTRA, an RNA interference therapy manufactured by Alnylam Pharmaceuticals (NASDAQ: ALNY), for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare but serious cause of heart failure, marking the first RNAi drug to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in this population.

Furthermore, in December 2024, the FDA granted tentative approval to SQ Innovation’s Lasix ONYU, a combination of a high-concentration furosemide formulation and an on-body drug delivery device developed by Gerresheimer, for home treatment of fluid overload in congestive heart failure. Full approval is expected after a competing product’s exclusivity ends in October 2025, with market launch anticipated by the end of 2025.

The congestive heart failure pipeline is robust, with several promising candidates in various stages of clinical development. In December 2024, AstraZeneca initiated a Phase IIb randomized, placebo-controlled study evaluating AZD5462 in stable patients with chronic heart failure. Similarly, Regeneron Pharmaceuticals began investigating REGN5381, an NPR1 monoclonal antibody agonist, in patients with chronic heart failure with reduced ejection fraction. Other notable pipeline drugs include KERENDIA (Bayer), MOUNJARO (Eli Lilly), Semaglutide (Novo Nordisk), CardiAMP Cell Therapy (BioCardia), and Mesoblast.

The use of stem cells to stimulate myocardial healing represents a promising new approach to treating heart failure. The late-stage cell therapy CardiAMP Cell Therapy by BioCardia (NASDAQ: BCDA) is expected to secure a significant market position, highlighting the growing interest in regenerative medicine approaches for cardiovascular conditions.

Several notable developments have occurred recently in the treatment landscape for congestive heart failure. In late April 2025, new clinical trial data presented at Heart Rhythm 2025 highlighted that left bundle branch area pacing (LBBAP) offers better outcomes than traditional biventricular pacing for patients needing cardiac resynchronization, reducing death and heart failure hospitalizations. Additionally, in March 2025, the FDA granted priority review to KERENDIA for heart failure with preserved ejection fraction, with a decision expected in the third quarter of 2025.

Discover evolving trends in the congestive heart failure treatment landscape @Congestive Heart Failure Recent Developments.

Despite these advancements, significant challenges remain in the congestive heart failure market. The high price of recently developed therapies, general reluctance of cardiologists to adopt new treatment options, and widespread use of generic heart failure drugs make it difficult for premium-priced branded therapies to penetrate the market effectively. Additionally, the chronic heart failure market faces challenges from underdiagnosis and delayed recognition due to overlapping symptoms with other conditions.

Looking forward, the chronic heart failure market is poised for substantial growth, driven by the anticipated expanded indication for therapies like Bayer’s KERENDIA, the launch of several oral and injectable agents, and the increasing global prevalence of chronic heart failure, potentially reshaping the treatment landscape in the coming years.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Congestive Heart Failure

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Congestive Heart Failure (CHF) Market Overview At A Glance

7. Disease Background and Overview

8. Congestive Heart Failure Treatment

9. Heart Failure with Preserved Ejection Fraction: Diagnosis And Management

10. Congestive Heart Failure Guidelines

11. Congestive Heart Failure Epidemiology and Patient Population

12. Congestive Heart Failure Patient Journey

13. Congestive Heart Failure Marketed Drugs

14. Congestive Heart Failure Emerging Drugs

15. Congestive Heart Failure (CHF): 7MM Analysis

16. Congestive Heart Failure Unmet Needs

17. Swot Analysis

18. Kol Views

19. Market Access and Reimbursement

20. Appendix

21. Delveinsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congestive Heart Failure Market Poised for Substantial Growth by 2034, Driven by Emerging Cell Therapies and Recent FDA Approvals | DelveInsight

OUPES Introduces the Exodus 2400: Simple, Powerful Backup Energy for Every Home

Backed by years of experience delivering reliable solar solutions, OUPES today unveils the Exodus 2400 power station, a powerful new home energy hub designed to keep lights, medical devices, and everyday appliances running when the grid fails. This new solar generator is available now, backed by an extended five-year warranty (plus an optional sixth year), and reflects OUPES’ vision “for a world where energy flows effortlessly…where affordability meets sustainability.”

With a storage capacity of 2,232 watt-hours and a steady 2,400-watt output—surging to 4,500 watts for brief power spikes—the Exodus 2400 brings peace of mind to homeowners facing unexpected outages.

Reliable Backup for Every Home

Power outages can happen without warning—and when they do, basic comforts quickly become urgent needs. The OUPES Exodus 2400 acts like a silent, invisible generator inside your house. It stores enough energy to run most home appliances—like refrigerators, lights, and even small heaters—long enough for you to stay comfortable and safe. A special “boost” function handles extra-hungry devices up to 2600W, such as microwaves or power tools, so you can keep going without worrying about tripping a breaker.

Fast, Flexible Charging

No one has time to wait all day for a recharge. The Exodus 2400 lets you combine wall-plug charging with solar panels to refill 80% of its power in under 50 minutes. Whether you plug it in at home, hook it up to car outlets, or connect it to most solar arrays, you have 4 easy ways to top up this solar generator. And when it’s resting, it uses very less energy itself, so you won’t lose precious backup capacity just sitting on the shelf.

Easy to Use and Monitor

Forget complicated settings and confusing displays. The Exodus 2400 power station comes with a smartphone app that shows exactly how much energy you have left, lets you switch charging modes, and even schedules automatic top-ups. 13 different outlets—standard plugs, USB ports, and more—mean you can charge laptops, phones, medical equipment, and more, all at once. When the power goes out, it switches over in less than a blink (

Giving Back and Peace of Mind

OUPES believes access to reliable energy should be universal. That’s why 5% of every Exodus 2400 sale goes to the OUPES HELP Program, bringing solar generator kits and backup systems to communities without steady electricity. To top it off, each unit comes with a 5 years warranty—and you can extend it to 6 years—so you know you’re covered long-term.

With its simple controls, rapid charging, and community support, the Exodus 2400 makes backup power stress-free and impactful. Keep the lights on, stay connected, and help others do the same.

The Exodus 2400 power station is now available at Amazon and OUPES.

About OUPES

OUPES’s mission is to democratize clean energy. For over a decade, OUPES has bridged the gap between sustainability and affordability, from emergency backup to backcountry exploration. OUPES factory-direct model cuts costs without compromising quality, backed by a 5-year warranty, 30-day return policy, and lifetime technical support.

Media Contact
Company Name: OUPES
Contact Person: Rita Zheng
Email: Send Email
Country: United States
Website: www.oupes.com

Operational Technology (OT) Security Market Latest Trends, Future Outlook, Size, Share, Applications, Advance Technology And Forecast -2030

“Fortinet (US), Forcepoint (US), Cisco (US), Tenable (US), Forescout (US), Seckiot (France), Check Point (Israel), Broadcom (US), Trellix (US), Microsoft (US), Okta (US), Palo Alto Networks (US), Qualys (US), Zscaler (US), BeyondTrust (US), CyberArk (US), Rapid7 (US), Sophos (UK), Tripwire (US), Radiflow (Israel), Kaspersky (Russia), SentinelOne (US), Thales (France), Armis (US).”

Operational Technology (OT) Security Market Latest Trends, Future Outlook, Size, Share, Applications, Advance Technology And Forecast -2030

The operational technology (OT) security market is anticipated to expand significantly, growing from USD 23.47 billion in 2025 to USD 50.29 billion by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 16.5% over the forecast period. This surge is primarily driven by the escalating frequency and sophistication of cyber threats targeting critical infrastructure. Industries such as energy, transportation, and water utilities are increasingly implementing advanced security measures to protect their operational systems against potential disruptions and data breaches. A notable example occurred in 2023, when a coordinated cyberattack targeted Taiwan’s state-run energy firms, aiming to impair the national power supply. The incident underscored vulnerabilities in industrial systems and accelerated the deployment of OT security solutions across the region.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18524133

By offering, solutions segment to account for larger market size than services segment during forecast period.

The solutions segment is projected to lead the OT security market share during the forecast period. Industrial control systems and critical infrastructure are protected by OT security solutions, which include a variety of software, stand-alone tools, and integrated systems. These solutions are specially designed to deal with the particular difficulties that OT environments face. Security information and event management (SIEM), asset discovery and management, network security, vulnerability management, identity and access management (IAM), data security, and other solutions are all included in the solutions segment. The growing number of cyberattacks that target vital infrastructure, particularly as industrial systems are increasingly integrated into IT networks, is driving up demand for OT security solutions.

By organization size, large enterprises segment to account for larger market size than SMEs segment during forecast period.

By organization size, the large enterprises segment is expected to lead the OT security market during the forecast period. Large enterprises serve as the backbone of numerous industries, managing intricate and widespread OT systems. With a strong emphasis on cybersecurity, they have sizable IT teams and budgets to back their efforts. Large enterprises are redefining their security strategies by integrating OT solutions and services to safeguard crucial assets from diverse cyber threats, such as ransomware attacks. Their adoption of OT security primarily aims to protect networks, endpoints, data centers, devices, users, and applications from unauthorized access and malicious attacks. Moreover, the growing adoption of access management solutions among large organizations facilitates privileged access to servers and web applications, further propelling market growth.

By region, Asia Pacific market to register highest CAGR during forecast period.

By region, Asia Pacific is expected to witness the highest CAGR in the OT security market during the forecast period. This growth is fueled by accelerated industrialization, widespread digital transformation, and the increasing adoption of Industry 4.0 technologies such as IoT, AI, and cloud computing across key sectors, including manufacturing, energy, and transportation. Countries like China, India, and Japan are leading this expansion, driven by significant investments in automation and smart infrastructure initiatives. The increasing number of connected devices and the convergence of IT and OT networks have broadened the attack surface, prompting heightened demand for advanced OT security solutions that include AI-driven threat detection, anomaly detection, and secure remote access.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=18524133

Unique Features in the Operational Technology (OT) Security Market

Unlike traditional IT security, OT security is uniquely designed to safeguard industrial control systems (ICS), supervisory control and data acquisition (SCADA) systems, and other embedded systems used in manufacturing, utilities, and critical infrastructure. These environments prioritize availability and safety over data confidentiality, requiring highly tailored solutions that can monitor and protect physical processes in real-time.

A distinctive trend in this market is the growing convergence of IT and OT systems. As operational networks become increasingly digitized and connected to corporate IT systems, OT security solutions must bridge the gap between these traditionally separate environments. This integration introduces new vulnerabilities but also opens the door for unified security frameworks that offer comprehensive visibility across both domains.

OT environments feature a wide variety of proprietary protocols and legacy devices that differ significantly from standardized IT systems. OT security tools are uniquely built to handle these diverse technologies, often operating in environments with limited processing power, outdated firmware, and no patch management, requiring passive monitoring and non-intrusive security measures.

Operational technology systems often control processes where failure can lead to physical harm, environmental damage, or service outages. Security solutions in this market must account for safety implications, ensuring that protective measures do not interfere with critical system functions. This balance between security and operational continuity is a defining feature of OT security.

Major Highlights of the Operational Technology (OT) Security Market

One of the primary market drivers is the surge in sophisticated cyberattacks on sectors such as energy, transportation, water, and manufacturing. These attacks, often targeting national infrastructure, can result in large-scale operational disruptions. Incidents like the 2023 cyberattack on Taiwan’s energy sector exemplify the urgent need for robust OT security solutions that protect physical operations as much as digital assets.

The market is benefiting from innovations such as AI-driven threat detection, behavioral analytics, asset visibility tools, and real-time monitoring systems. These technologies are enhancing the ability to detect anomalies and respond to threats quickly in highly sensitive environments where downtime is not an option.

Industries with high dependency on uninterrupted operations—such as oil & gas, power generation, transportation, and water utilities—are leading the adoption of OT security solutions. These sectors face strict compliance requirements and are increasingly deploying layered security architectures that combine endpoint protection, network segmentation, and incident response.

Regulatory frameworks around the world are becoming more stringent, compelling organizations to invest in OT security. Standards such as NIST, IEC 62443, and sector-specific mandates are setting the benchmark for minimum security practices. Compliance is not only about avoiding fines but also about building resilience against nation-state actors and ransomware threats.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=18524133

Top Companies in the Operational Technology (OT) Security Market

The OT Security market is led by some of the globally established players, such as Fortinet (US), Forcepoint (US), Cisco (US), Tenable (US), Forescout (US), Seckiot (France), Check Point (Israel), Broadcom (US), Trellix (US), Microsoft (US), Okta (US), Palo Alto Networks (US), Qualys (US), Zscaler (US), BeyondTrust (US), CyberArk (US), Rapid7 (US), Sophos (UK), Tripwire (US), Radiflow (Israel), Kaspersky (Russia), SentinelOne (US), Thales (France), Armis (US), Darktrace (UK), Nozomi Networks (US), Honeywell (US), Schneider Electric (France), Siemens (Germany), ABB (Switzerland), Tosibox (Finland), Rhebo (Germany), Shield-IoT (Israel), Claroty (US), Dragos (US), Cydome (Israel), Ordr (US), Mission Secure (US), runZero (US), SIGA OT Solutions (US), Sectrio (US), Waterfall Security Solutions (Israel), and Opswat (US). Partnerships, agreements, collaborations, acquisitions, and product developments are various growth strategies these players use to increase their market presence.

Fortinet (US) is a global leader in automated and integrated cybersecurity solutions. The company’s managed service portfolio includes firewalls, APT detection, Wireless Local Area Networks (WLAN) and switching, virtualized security, Identity and Access Management (IAM), and application security. Fortinet Security Fabric helps manage an attack, protect the entire infrastructure through integrated visibility, stop advanced threats through integrated AI-driven breach prevention, and reduce complexity through automated operations and orchestration without compromising performance. The solution provides segmentation of the entire network to prepare it for a zero-trust approach.

Forcepoint (US) is a subsidiary of Francisco Partners. It offers solutions for cloud security, network security, data and insider threat security, and global government security. Its service offerings include data security consulting, cybersecurity intelligence services, training and technical certification, government certification, and support services. Forcepoint serves financial services, government, healthcare, and retail industries. The company offers products over two lines: Global Governments and Critical Infrastructure & Commercial Security. The company’s portfolio encompasses a wide range of products and services designed to address the evolving cybersecurity landscape. These offerings include next-generation firewalls, secure web gateways, data loss prevention tools, cloud access security brokers, and user and entity behavior analytics.

Cisco

Cisco (US) is a leading player in the Operational Technology (OT) security market, leveraging its extensive networking and cybersecurity expertise to protect industrial environments. The company offers integrated security solutions designed to safeguard critical infrastructure, including manufacturing, energy, transportation, and utilities, from cyber threats. Through its Secure Firewall, Cyber Vision, and Industrial Security Appliances, Cisco provides real-time visibility, threat detection, and segmentation across both IT and OT networks. Its approach focuses on unifying IT and OT security under a common architecture, enabling organizations to monitor and respond to threats across their entire digital landscape.

Tenable

Tenable (US) is a prominent player in the Operational Technology (OT) security market, specializing in vulnerability management and cyber risk assessment for industrial environments. Through its Tenable OT Security platform (formerly Indegy), the company provides deep visibility into OT assets, continuous monitoring, and threat detection to protect critical infrastructure from cyberattacks. Tenable’s solutions integrate IT and OT security, allowing organizations in sectors like energy, manufacturing, and utilities to identify vulnerabilities, assess risks, and prioritize remediation efforts effectively. Its unified approach helps bridge security gaps between IT and OT, ensuring comprehensive protection of industrial networks.

Forescout

Forescout (US) is a prominent player in the Operational Technology (OT) security market, offering comprehensive solutions that provide real-time visibility, threat detection, and control across IT, OT, and IoT environments. Their platform, Forescout for OT Security, is designed to secure complex, heterogeneous infrastructures—whether cloud-based, air-gapped, or hybrid—by delivering proactive exposure management, AI-enhanced asset intelligence, and threat detection powered by their proprietary Vedere Labs research. Recognized as a Leader and Fast Mover in the 2024 GigaOm Radar Report for OT Security, Forescout supports over 300 OT/IoT protocols and enables organizations to discover and manage both managed and unmanaged devices across all Purdue levels. Their solutions are particularly effective in sectors like healthcare, manufacturing, and critical infrastructure, where nonintrusive asset discovery and extensive protocol support are critical. Additionally, Forescout’s partnerships with industry leaders like Splunk, CrowdStrike, and CyberArk enhance their threat intelligence and response capabilities, providing a unified approach to securing cyber-physical systems.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/operational-technology-ot-security-market-18524133.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Operational Technology (OT) Security Market Latest Trends, Future Outlook, Size, Share, Applications, Advance Technology And Forecast -2030

The Fintech Future: Stocks to Watch as the Sector Surges Toward $1.1T

Fintech is charging forward—and it’s on track to surpass $1.1 trillion by 2032. The global fintech market, already valued at around $340 billion in 2024, is being turbocharged by surging demand for digital wallets, AI-driven financial solutions, and cross-border payments. From revolutionizing banking to streamlining international commerce, fintech is no longer a niche—it’s the backbone of modern finance.

For investors looking to tap into this rapid growth, the opportunities are enormous. With new innovations reshaping the way money moves and grows, it’s clear: fintech isn’t just here to stay, it’s accelerating at an unprecedented pace.

For investors looking to tap into this momentum, here are four stocks worth a closer look.

Pineapple Financial Inc. (NYSE American: PAPL) is a Canadian fintech firm redefining the mortgage brokerage space with its innovative, tech-first approach. As one of Canada’s leading mortgage networks, Pineapple combines AI-driven tools with cloud-based systems to empower hundreds of brokers across the country. The company not only streamlines the home-buying experience for Canadians but also supports its agents with scalable technology designed for long-term success.

Despite a challenging real estate market, Pineapple has demonstrated impressive financial momentum in recent quarters. For the six months ending February 28, 2025, the company reported an 11.8% year-over-year revenue increase, alongside a 15.2% rise in gross billings—reaching $9.33 million. At the same time, operating efficiencies helped reduce net losses and improve cash flow. Pineapple cut SG&A expenses by 3.6%, lowered advertising costs by over 60%, and saw a 47% improvement in cash used for operations.

“Our second-quarter results highlight the successful transition to an integrated platform, driving meaningful cost savings and enhancing our ability to scale,” said CEO Shubha Dasgupta. “We are now in a position to continue growing revenue at scale while reducing expenses as we move toward profitability.”

Investors have taken notice. On May 5, 2025, Pineapple successfully closed a $1.5 million public offering, raising fresh capital to support growth. The company is actively scaling in response to a surge in Canadian mortgage renewals—a trend expected to continue over the next two years. CFO Sarfraz Habib added, “These improvements ensure that we are well-positioned to achieve profitability in the near term, even amid a challenging macroeconomic environment.”

In the first quarter of fiscal 2025, Pineapple reported a 34.6% increase in revenue and a 26.8% reduction in net loss, further underscoring the company’s accelerating momentum. Its growing footprint, cost discipline, and ability to execute in a volatile market position Pineapple as a compelling fintech stock to watch.

As Canada’s mortgage landscape continues to evolve—with lower interest rates, policy shifts, and increased housing demand—Pineapple stands to benefit from the rising need for modern, tech-powered financial solutions. With a strong leadership team and a scalable platform, Pineapple Financial (NYSE American: PAPL) is aiming to turn today’s investments into tomorrow’s profitability.

Opendoor Technologies Inc. (Nasdaq: OPEN) is redefining how Americans buy and sell homes through its pioneering e-commerce platform for residential real estate. Operating in markets across the U.S. since 2014, Opendoor simplifies what is often one of life’s most complex transactions, providing homeowners with flexibility, speed, and certainty. From instant cash offers to partnerships with trusted agents, Opendoor empowers customers with choice—all backed by technology and data-driven insights.

Opendoor entered 2025 with a clear focus: driving toward profitability while enhancing its customer experience. The company’s first-quarter results demonstrate meaningful progress. For Q1 2025, Opendoor reported $1.2 billion in revenue, marking a 6% increase quarter-over-quarter. The company sold nearly 3,000 homes, with a gross profit of $99 million and a gross margin of 8.6%, up from 7.8% in Q4 2024.

Opendoor also continued to narrow its losses, with net loss improving to $85 million, down from $113 million the previous quarter. On a non-GAAP basis, Adjusted EBITDA improved to $(30) million, from $(49) million in Q4. Contribution profit came in at $54 million, representing a 42% increase quarter-over-quarter.

The company ended Q1 with a robust inventory of 7,080 homes valued at $2.4 billion, up 26% year-over-year. Opendoor purchased 3,609 homes in the quarter—a 22% increase sequentially—positioning itself well for future sales growth. While homes under contract for future purchase declined, the company remains focused on disciplined acquisition strategies and operational efficiencies.

Opendoor’s Q2 2025 guidance reflects continued growth and a potential turning point in profitability. The company expects:

Revenue between $1.45 billion and $1.525 billion
Contribution profit of $65 million to $75 million
Adjusted EBITDA between $10 million and $20 million

With improving margins, disciplined cost control, and a clear strategic roadmap, Opendoor is moving closer to positive EBITDA and long-term scalability. As the real estate market evolves and digitization accelerates, Opendoor stands at the forefront of reshaping the U.S. housing transaction experience.

Payoneer Inc. (NASDAQ: PAYO) is a global financial technology company on a mission to democratize access to cross-border commerce for the world’s small and medium-sized businesses (SMBs). Founded in 2005, the company has built an end-to-end financial stack that helps millions of entrepreneurs and enterprises—especially in emerging markets—get paid, manage multi-currency funds, and grow globally. With customers in over 190 countries and a presence across 7,000+ trade corridors, Payoneer is a critical infrastructure layer for modern global commerce.

In Q1 2025, Payoneer continued to deliver robust growth, with revenue (excluding interest income) rising 16% year-over-year. This performance was driven by 7% volume growth and a 22% increase in average revenue per user (ARPU). Notably, revenue from SMBs grew 18%, led by strong momentum in high-value segments:

Marketplace SMBs generated $110 million in revenue, up 8% YoY
B2B SMBs grew 37% to $52 million
Checkout services nearly doubled YoY to $7 million
Payoneer Cards processed $1.4 billion in spend, up 29% YoY

This marks the seventh consecutive quarter of ARPU acceleration and underscores the growing adoption of Payoneer’s broader financial services offerings.

In early April, Payoneer completed its acquisition of Easylink Payment Co., Ltd., a licensed China-based payment service provider. This move strengthens the company’s regulatory foundation in a key market and enhances its ability to deliver localized, compliant solutions for Chinese exporters navigating global trade.

Just weeks later, Payoneer celebrated its 20th anniversary, commemorating two decades of powering global entrepreneurship. The milestone included a $2 million donation to Endeavor, a leading global network supporting high-impact entrepreneurs, and culminated in a Nasdaq closing bell ceremony. These celebrations highlighted Payoneer’s long-term commitment to enabling ambition without borders.

Despite strong underlying performance, Payoneer is taking a cautious stance amid global economic uncertainty and has suspended its full-year 2025 guidance. Management cited shifting global trade dynamics and potential headwinds for cross-border businesses as key factors. However, the company remains confident in its long-term strategy, underpinned by a diverse customer base and a differentiated product offering.

Payoneer ended Q1 with $6.6 billion in customer funds, up 11% YoY, and continued to return capital to shareholders with $17 million in share repurchases during the quarter.

As global trade evolves, Payoneer is uniquely positioned to support SMBs navigating new supply chains, regulatory environments, and digital ecosystems. With a proven track record of innovation, disciplined execution, and a global-first approach, Payoneer is well-equipped to lead the next chapter of cross-border commerce.

PagBank (NYSE: PAGS) the digital banking arm of Brazil’s UOL Group, is rapidly solidifying its position as a dominant player in Latin America’s fintech space. With a focus on simplifying financial life for individuals and businesses alike, the company offers a broad suite of services—from digital accounts and mobile payments to credit products and insurance—backed by a robust regulatory framework under Brazil’s Central Bank.

In Q4 2024, PagBank posted impressive results, recording net revenue of R$5.1 billion—a year-over-year increase of 18%. Even more compelling was its 21% jump in net income, reaching R$631 million. These gains came despite a volatile macroeconomic environment marked by high interest rates and currency swings. Notably, the company achieved a return on average equity (ROAE) of 15.2%, underscoring its operational efficiency and financial discipline.

Growth metrics were equally strong:

Total Payment Volume (TPV): R$146 billion in Q4 alone (+28% YoY), R$518 billion for the year (+32% YoY)
Customer Base: 33.2 million, with 2.1 million new users added in 2024
Credit Portfolio: R$48 billion (+46% YoY)
Deposits: R$36.1 billion (+31% YoY)

PagBank’s expanding ecosystem includes 6.3 million merchant clients and nearly 18 million active users who rely on it as their primary banking platform. Continued innovation—such as their Multiple Card (debit + credit) and cashback offerings—has enhanced customer engagement and loyalty.

From a financial performance perspective, PagBank has become a consistent earnings beat story. It has topped Wall Street’s EPS estimates for the last two quarters by an average of nearly 12%, with a 17.24% beat in the most recent quarter. Its focus on operational leverage, funding cost reduction, and risk management has built a strong foundation for future growth.

Looking ahead, the company maintains a bullish outlook for 2025. It plans to continue investing in technology, expanding its product portfolio, and leveraging its scale to maximize returns. With a current share price under $5, PAGS presents an intriguing opportunity for investors seeking fintech growth in emerging markets, backed by strong fundamentals, consistent profitability, and scalable innovation.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of content related to PAPL. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Fintech Future: Stocks to Watch as the Sector Surges Toward $1.1T

Fresh Coat Painters of Hudson & Medina Offers Premier Exterior Painting Services in Fairlawn

Fresh Coat Painters of Hudson & Medina is now offering professional and reliable exterior painting services to homeowners and property managers in Fairlawn, Ohio. With a strong focus on craftsmanship and high-quality finishes, the company is setting a new standard for residential and commercial painting projects in the region.

Fairlawn, OH – May 7, 2025 – Property owners looking to enhance curb appeal and protect their investments can now rely on top-rated Exterior Painting Fairlawn services provided by a team of experienced professionals. Fresh Coat Painters of Hudson & Medina delivers clean, precise results using premium materials and modern application techniques.

As demand continues to grow in the local market, many are turning to dedicated Exterior House Painters Fairlawn who understand the unique weather conditions and architectural styles found in the area. The team carefully prepares all surfaces and executes each project with attention to detail, helping properties maintain long-lasting beauty and structural integrity.

For those seeking a fresh, vibrant look for patios, siding, trim, and more, Fresh Coat Painters of Hudson & Medina also specializes in services offered by expert Outdoor Painters Fairlawn. Each project is managed efficiently and completed on schedule, making the painting process smooth for both residential and commercial clients.

Fresh Coat Painters of Hudson & Medina is committed to delivering results that exceed expectations in both appearance and durability. With transparent pricing and flexible scheduling, the company continues to build a reputation as a trusted partner in property improvement throughout the Fairlawn area.

Media Contact
Company Name: Fresh Coat Painters of Hudson & Medina
Contact Person: Brad Burgess
Email: Send Email
Phone: (330) 302-6381
Address:55 Shiawassee Avenue Unit 10H
City: Fairlawn
State: OH
Country: United States
Website: https://freshcoatpainters.com/locations/hudson-medina/